Hebei, China

Yumei Wang

This inventor holds 1 USPTO granted patent. Top assignee: Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yumei Wang. Retrieved from https://idiyas.com/inventor/yumei-wang-mjwj4ohc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Yumei Wang: A Trailblazer in Lymphoma Treatment

Introduction: Yumei Wang, an accomplished inventor based in Hebei, China, has made notable contributions to the field of medical pharmaceuticals. With a focus on innovative cancer treatments, Wang has put forth groundbreaking research aimed at improving therapies for non-Hodgkin's lymphoma. His work is particularly significant as it addresses a critical area in oncology, providing hope for patients suffering from aggressive forms of this disease.

Latest Patents: Wang holds a patent for the "Use of mitoxantrone liposome for treating non-Hodgkin's lymphoma." This patent reveals the use of a specialized liposomal pharmaceutical preparation of mitoxantrone, specifically aimed at treating lymphoma. The emphasis is mainly on aggressive non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma and peripheral T-cell lymphoma. This novel approach utilizes mitoxantrone liposomes as a single anti-tumor therapeutic agent, distinguishing it from traditional treatments that often combine multiple agents.

Career Highlights: Yumei Wang is currently affiliated with Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Throughout his career, he has demonstrated a commitment to advancing pharmaceutical technology, particularly in oncology. His pioneering work in the application of liposomal formulations is indicative of his dedication to enhancing treatment efficacy and patient outcomes in complex cases of lymphoma.

Collaborations: In his research endeavors, Yumei Wang collaborates with distinguished colleagues, including Chunlei Li and Yueying Peng. This collaborative spirit fosters an environment of innovation and shared knowledge, further propelling the advancements in cancer treatments that Wang is passionate about.

Conclusion: Through his innovative approach to treating non-Hodgkin's lymphoma, Yumei Wang exemplifies the role of inventors in shaping the future of medicine. His patent not only represents a significant step forward in cancer therapy but also reflects the collaborative effort essential in research and development. Yumei Wang’s work continues to inspire and offer potential solutions for patients who face formidable challenges in their fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…